You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
A Synthetic Human Cytomegalovirus Vaccine Platform
SBC: TOMEGAVAX, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial Dysfunction in HAART: Point of Care Tests
SBC: MITOSCIENCES, INC Topic: NIGMSDESCRIPTION (provided by applicant): Highly Active Anti-Retroviral Therapy (HAART) used to treat HIV/AIDS has serious side-effects, including metabolic complications from mitochondrial toxicities that can be life-threatening, and limit effectiveness and patient compliance. Adverse metabolic effects are now managed by adept clinicians who monitor patients closely for clinical symptoms and adjust t ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Targeting lipid rafts for treatment of asthma
SBC: RAFT PHARMACEUTICALS LLC Topic: NIAIDPROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the Innate Immune System by Fisetin for the Treatment of AD
SBC: VIROGENICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune system play a major role its progression. Based on this evidence, we propose a new approach to the treatm ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Advancing clemizole for hepatitis C: towards a pre-IND package
SBC: EIGER GROUP INTERNATIONAL, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of Staphylococcus aureus agr-based Quorum Sensing as Vaccine Candidate
SBC: SORRENTO THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our passive vaccination strategies targeting Staphylococcus aureus/MRSA to prevent or treat infections associated with S. aureus/MRSA. With the emergence of highly antibiotic-resistant bacterial strains, most notably MRSA, new approaches for combating bacterial infections are desperately nee ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Biomarker discovery for immunodiagnosis of invasive candidiasis
SBC: DXDISCOVERY INC Topic: NIAIDDESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.
SBC: Douleur Therapeutics Inc Topic: NINDSProject Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Targeting lipid rafts for treatment of migraine
SBC: RAFT PHARMACEUTICALS LLC Topic: NINDSPROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decreased working efficiency and workdays lostManagement of migraine has become increasingly pharmacological during recent yearsWhile several therapeutic options existmost of the prophylactic drugs current ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health